JIOH on LinkedIn JIOH on Facebook
  • Users Online: 338
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL RESEARCH
Year : 2022  |  Volume : 14  |  Issue : 2  |  Page : 182-188

COVID-19 vaccination compliance rate and self-reported post-vaccination adverse effects among the members of dental faculty in Malaysia: A cross-sectional study


Faculty of Dentistry, SEGi University, No. 9 Jalan Teknologi, Kota Damansara 47810, Petaling Jaya Selangor, Malaysia

Correspondence Address:
Dr. Suresh Kandagal Veerabhadrappa
Faculty of Dentistry, SEGi University, No. 9 Jalan Teknologi, Kota Damansara 47810, Petaling Jaya Selangor
Malaysia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jioh.jioh_244_21

Rights and Permissions

Aim: To evaluate the COVID-19 vaccination compliance rate and post-vaccination Adverse Effects (AEs) among the Dental Health Care Workers (DHCW). Materials and Methods: An online, cross-sectional, self-administered, structured questionnaire was distributed to 54 DHCW at the Faculty of Dentistry, SEGI University to evaluate the demographic characteristics, history of infection, type of vaccine received, post-vaccination AEs, duration, and hospitalization. In this pilot study, a convenience sampling method was adopted and descriptive statistics was employed to describe the results. Chi-square test was used to compare the post-vaccination AEs among the CoronaVac® group, Pfizer-BioNTech group and AstraZeneca group and a p-value of less than 0.05 was considered statistically significant. Results: About 85% participants had completed the vaccination and one participant tested positive for COVID-19 after the first dose. Following the first dose, participants in Pfizer-BioNTech (88.9%) and AstraZeneca group (100%), experienced higher local AEs (pain and tenderness at the site of injection) than the CoronaVac® (33.3%) group which was statistically significant (P < 0.006). Although higher systemic AEs were observed in Pfizer-BioNTech (66.7%) and AstraZeneca vaccine (100%) than the CoronaVac® (30.6%) group, this was not significant. Similarly, after the second dose, higher percentage of participants in the Pfizer-BioNTech group experienced systemic (66.7%) and local AEs (66.7%) than CoronaVac® group. However, this was not significant too. The most common systemic AEs were fatigue and myalgia. One participant reported a mild allergic reaction and the majority of these AEs resolved in 24–48 hours after vaccination, without requiring hospitalization. Conclusions: DHCW exhibited a greater compliance rate to Covid-19 vaccination. Local AEs were more frequently encountered than the systemic ones and the common AEs were pain and tenderness at the injection site, fatigue, and myalgia. Clinical Significance: Recognizing and reporting the AEs of COVID-19 vaccines are imperative to enhance the vaccine uptake among the public.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed159    
    Printed0    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal